Has Adolfo Ramirez Zamora, MD received payments from drug or device companies?

Yes. Drug and device makers reported $363,248 in general payments to Adolfo Ramirez Zamora, MD across 448 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Adolfo Ramirez Zamora, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Adolfo Ramirez Zamora, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Adolfo Ramirez Zamora, MD

Neurology · Gainesville, FLNPI 1922261270

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $245,155 of the $363,248 with a category attached, or 67.5%. Medtronic accounts for 84.0% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $86,682, 2.8 times the $30,729 reported in 2019. Among neurology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$363,248in general payments, 2019–2025

Across 448 payments — averaging $810.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$305K
Novo Nordisk AS$46K
Boston Scientific$9K
Biogen$913
AstraZeneca$800
Vertex$500
plus $219 from 2 others

$480,180in research payments, 2019–2025

Across 30 payments — averaging $16,006 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$153K
AbbVie$124K
Medtronic$99K
Functional Neuromodulation Inc$77K
Genentech, Inc.$26K
Boston Scientific$2K

What the payments were for

Consulting fees$41,24211%
Speaking & faculty fees$245,15567%
Grants$2420%
Travel & lodging$66,11518%
Food & beverage$10,4933%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	413	$305,263
Novo Nordisk AS	11	$46,458
Boston Scientific	19	$9,094
Biogen	1	$913
AstraZeneca	1	$800
Vertex	1	$500
Neurocrine Biosciences, Inc.	1	$171
AbbVie	1	$47

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

PERCEPT PC BRAINSENSE$182,873
ACTIVA$47,683
Percept$29,744
SenSight$22,100
INTELLIS ADAPTIVESTIM$7,650
VERCISE$4,158
ACTIVA PC$786
VISUALASE$242
INGREZZA$171
ONGENTYS$171
DFS$107

How this compares

$363,248 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024

$239,648

Medicare patients

278

Services billed

24,845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RytaryCarbidopa/Levodopa	24	$31,434
Carbidopa-LevodopaCarbidopa/Levodopa	171	$5,617
Carbidopa-Levodopa ErCarbidopa/Levodopa	79	$5,533
Ropinirole ErRopinirole Hcl	17	$3,549
Rivastigmine	13	$3,154
Selegiline Hcl	22	$2,228
Rasagiline Mesylate	12	$1,649
Baclofen	17	$703
Quetiapine Fumarate	35	$621
Nortriptyline Hcl	41	$583
Bupropion XlBupropion Hcl	29	$566
Pregabalin	13	$564
Pramipexole DihydrochloridePramipexole Di-Hcl	14	$511
Memantine Hcl	16	$511
Donepezil Hcl	51	$473

Paid to pharmacies, not to this prescriber.

Other neurology in Gainesville

Stuart IsaacsonBoca Raton$3.9M
Selim BenbadisTampa$2.1M
Derrick RobertsonTampa$1.8M
Robert HauserTampa$1.6M
David RoseTampa$1.4M
Matthew BakerNaples$1.4M
Donald NegroskiSarasota$1.4M
Mark CascioneTampa$1.2M
Lance KimOcala$1M
Tuan VuTampa$1M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →